A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study)

Yoshikawa, T.; Omura, K.; Kobayashi, O.; Nashimoto, A.; Takabayashi, A.; Yamada, T.; Yamaue, H.; Fujii, M.; Yamaguchi, T.; Nakajima, T.

doi:10.1016/j.ejso.2010.04.011

« Previous Next »European Journal of Surgical Oncology
Volume 36, Issue 6 , Pages 546-551, June 2010

A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study)

T. Yoshikawa
- Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-ku, Yokohama 241-0815, Japan
- Corresponding author. Tel.: +81 45 391 5761; fax: +81 45 361 4692.
K. Omura
- Department of Surgery, Kanazawa University, 13-1 Takara-machi, Kanazawa, Japan
O. Kobayashi
- Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-ku, Yokohama 241-0815, Japan
A. Nashimoto
- Department of Surgery, Niigata Cancer Center, 2-15-3 Kawagishi-cho, Chuo-Ku, Niigata 951-8566, Japan
A. Takabayashi
- Department of Surgery, Kitano Hospital, 2-4-20 Ogicho, Kita-Ku, Osaka 530-8480, Japan
T. Yamada
- Department of Surgery, Ishikawa Prefectural Central Hospital, 2-1 Kuratsukihigashi, Kanazawa 920-8530, Japan
H. Yamaue
- Department of Surgery, Wakayama University, 811-1 Kimiidera, Wakayama 641-8510, Japan
M. Fujii
- Department of Surgery, Nihon University, 1-8-13 Kandasurugadai, Chiyoda-Ku, Tokyo 101-8309, Japan
T. Yamaguchi
- Department of Gastrointestinal Tract Surgery, Cancer Institute Hospital, 3-10-6 Ariake, Koto-Ku, Tokyo 135-8550, Japan
T. Nakajima
- Japan Clinical Cancer Research Organization, 3-10-6 Ariake, Koto-Ku, Tokyo 135-8550, Japan

Accepted 12 April 2010.

Abstract

Aims

Clinically serosa-positive (T3–4) gastric cancer has a poor prognosis. This phase II trial explored the feasibility and safety of preoperative chemotherapy followed by D2 or D3 gastrectomy in this type of gastric cancer.

Methods

Patients with T3–4 gastric cancer received one course of S-1 (80mg/m² daily for 3 weeks) and cisplatin (60mg/m² on day 8) chemotherapy and then underwent D2 or D3 gastrectomy with curative intent. Primary endpoint was toxicities.

Results

Of 50 patients enrolled, 49 were eligible and received the treatment protocol. Chemotherapy-related toxicities were mild; grade 3 neutropenia in 2 patients, anorexia in 3, and nausea in 2, and no grade 4 toxicities. Clinical response was achieved in 13 of 34 evaluable patients. Of the 49 patients, 39 underwent D2 or D3 dissection. There was no surgical mortality. Operative morbidity occurred in 5 of 49 patients, including pancreatic fistula in 1 and abdominal abscess in 2.